Back to Directory

Camoxis Therapeutics

Small-molecule therapeutics targeting ischaemia-reperfusion injury

Camoxis Therapeutics is a biopharmaceutical company developing small-molecule treatments to reduce tissue damage caused by ischaemia-reperfusion injury. Its lead approach uses acidified disodium malonate to limit mitochondrial processes that generate damaging reactive oxygen species when blood flow returns after a stroke.

Originating from University of Cambridge research, the company is advancing a potential adjunct to mechanical thrombectomy, supported by preclinical studies in mouse models.